BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• Submit your Company Profile information

  Please provide the information below so we can set up your BioSpace company profile, For additional support please contact us at support@biospace.com.

  August 29, 2024
• Purchase Your Hotbed Map Campaign

  Select your 2025 Hotbed Map Campaign.

  August 29, 2024
• 

  NeoSome Life Sciences

  NeoSome Life Sciences is a Preclinical Contract Research Organization, providing individualized services to support the drug discovery process from proof of concept studies through early stage development.
• 

  Real estate

  Texas Life Sciences Redevelopment Project Moves Closer to Reality

  In Texas, the Plano City Council approved a development agreement that supports a planned project that would bring over 3 million square feet of life sciences space to the area.

  August 29, 2024

   · 

  1 min read

   · 

  Angela Gabriel
• 

  Drug Development

  Future-Proofing: Inclusive and Protective Patient Strategies

  In this episode, the third and final conversation of our mini-series on diversity in clinical trials, Lori and guests discuss framing strategies designed to protect DEI initiatives from legal challenges.

  August 29, 2024

   · 

  1 min read

   · 

  Lori Ellis
• 

  Legal

  Regeneron Sues Sandoz in Federal Court to Block Eylea Biosimilar

  In its legal complaint, filed in the District Court for New Jersey, Regeneron alleges that Sandoz failed to provide it with relevant information required under the Biologics Price Competition and Innovation Act.

  August 29, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cardiovascular disease

  Novartis Plots Leqvio Expansion After Lowering Cholesterol in Phase III Study

  Armed with new late-stage data on reducing low-density lipoprotein cholesterol, Novartis is positioning its siRNA therapy Leqvio as a preventive treatment for atherosclerotic cardiovascular disease.

  August 29, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cancer

  Merck Axes Two Keytruda Phase III Cancer Trials Due to Disappointing Data

  The pharma continued its clinical losing streak on Thursday with the announcement that it is discontinuing late-stage studies of the anti-PD-1 therapy in non-small cell lung cancer and cutaneous squamous cell carcinoma.

  August 29, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Pharmacy benefit managers

  House Oversight Chair Calls on PBM Execs to Correct Testimonies

  The chair of the House Committee on Oversight and Accountability wants the CEOs of CVS Caremark, Express Scripts and Optum Rx to fix statements they made in a hearing last month that contradicted the committee’s and Federal Trade Commission’s findings.

  August 29, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Layoffs

  BioMarin to Lay Off 225 Employees Globally

  Last week, BioMarin revealed changes to its C-suite; now, the company has announced its second round of layoffs this year, following the termination of 170 employees in May.

  August 29, 2024

   · 

  1 min read

   · 

  Angela Gabriel